To characterize the amplification of EZH2, EED, and SUZ12 in different tumor types we analyzed clinical samples for the amplified PRC2 subunit genes using the cBioPortal database (https://www.cbioportal.org/, accessed on 2 November 2020) [30]. This evidence concerns the gene EED and neoplasm.